Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.

Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Martín M, De Miguel MJ, Yu EY, Williams A, Gion M, Tan AR, Agrawal L, Rutten A, Machiels JP, Cresta S, Debruyne PR, Hennequin A, Moreno V, Minchom A, Valdes-Albini F, Petrylak D, Li L, Tsuchihashi Z, Suto F, Cheng FC, Kandil M, Barrios D, Hurvitz S

Open source

DOI: 10.1158/1078-0432.ccr-24-1513
Published: 2024 Dec 16
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-24-1513,
  title = {Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.},
  author = {Hamilton E and Galsky MD and Ochsenreither S and Del Conte G and Martín M and De Miguel MJ and Yu EY and Williams A and Gion M and Tan AR and Agrawal L and Rutten A and Machiels JP and Cresta S and Debruyne PR and Hennequin A and Moreno V and Minchom A and Valdes-Albini F and Petrylak D and Li L and Tsuchihashi Z and Suto F and Cheng FC and Kandil M and Barrios D and Hurvitz S},
  year = {2024},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-24-1513},
  url = {https://doi.org/10.1158/1078-0432.ccr-24-1513}
}

RIS

TY  - JOUR
TI  - Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
AU  - Hamilton E
AU  - Galsky MD
AU  - Ochsenreither S
AU  - Del Conte G
AU  - Martín M
AU  - De Miguel MJ
AU  - Yu EY
AU  - Williams A
AU  - Gion M
AU  - Tan AR
AU  - Agrawal L
AU  - Rutten A
AU  - Machiels JP
AU  - Cresta S
AU  - Debruyne PR
AU  - Hennequin A
AU  - Moreno V
AU  - Minchom A
AU  - Valdes-Albini F
AU  - Petrylak D
AU  - Li L
AU  - Tsuchihashi Z
AU  - Suto F
AU  - Cheng FC
AU  - Kandil M
AU  - Barrios D
AU  - Hurvitz S
PY  - 2024
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-24-1513
UR  - https://doi.org/10.1158/1078-0432.ccr-24-1513
ER  -

APA

E, H., MD, G., S, O., G, D. C., M, M., MJ, D. M., EY, Y., A, W., M, G., AR, T., L, A., A, R., JP, M., S, C., PR, D., A, H., V, M., A, M., F, V., D, P., L, L., Z, T., F, S., FC, C., M, K., D, B., & S, H. (2024). Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-1513

Source records

pubmed · retrieved 2026-09-27T06:23:22.782Z